title: A case of septal panniculitis secondary to interferon treatment.
abstract: The most common side effects of interferon-beta therapy following subcutaneous administration include pain, inflammation and induration at the injection site, which occur in approximately 20-60% of patients. Besides, transient injection-site erythema is frequently seen in beta-interferon therapy. Less frequent reactions at injection sites include vascular thrombosis, mucinosis, dermal and systemic sclerosis, necrosis, and ulceration. Here, we report a 44-year-old case diagnosed with multiple sclerosis, who developed pain and swelling following interferon-beta 1a treatment after an improperly administered intramuscular injection; and with this case report, we would like to draw attention to septal panniculitis, a serious drug complication, that develops following interferon-beta 1a treatment after an improperly administered intramuscular injection.
authors.affiliation: Department of Dermatology and.
authors.forename: Pinar
authors.initials: P
authors.lastname: Ozuguz
authors.forename: Seval Dogruk
authors.initials: SD
authors.lastname: Kacar
authors.forename: Semsettin
authors.initials: S
authors.lastname: Karaca
authors.forename: Cigdem
authors.initials: C
authors.lastname: Tokyol
mesh_terms: D000328:Adult; D005355:Fibrosis; D006801:Humans; D007249:Inflammation / Q000473:pathology; D007273:Injections, Intramuscular / Q000009:adverse effects*; D000068556:Interferon beta-1a; D016899:Interferon-beta / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D008297:Male; D009103:Multiple Sclerosis / Q000150:complications / Q000188:drug therapy; D015434:Panniculitis / Q000139:chemically induced* / Q000473:pathology*; D012867:Skin / Q000473:pathology
chemical_list: D016899:Interferon-beta; D000068556:Interferon beta-1a
keywords: Interferon-beta; septal panniculitis; side effect